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Ischemia/reperfusion injury is a leading cause of acute renal
failure triggering an inflammatory response associated with
infiltrating macrophages, which determine disease outcome.
To repair the inflammation we designed a procedure
whereby macrophages that overexpress the anti-
inflammatory agent interleukin (IL)-10 were adoptively
transferred. These bone marrow–derived macrophages were
able to increase their intracellular iron pool that, in turn,
augmented the expression of lipocalin-2 and its receptors.
Infusion of these macrophages into rats after 1 h of
reperfusion resulted in localization of the cells to injured
kidney tissue, caused increases in regenerative markers, and
a notable reduction in both blood urea nitrogen and
creatinine. Furthermore, IL-10 therapy decreased the local
inflammatory profile and upregulated the expression of pro-
regenerative lipocalin-2 and its receptors. IL-10–mediated
protection and subsequent renal repair were dependent on
the presence of iron and lipocalin-2, since the administration
of a neutralizing antibody for lipocalin-2 or administration of
IL-10 macrophages pretreated with the iron chelating agent
deferoxamine abrogated IL-10–mediated protective effects.
Thus, adoptive transfer of IL-10 macrophages to ischemic
kidneys blunts acute kidney injury. These effects are
mediated through the action of intracellular iron to induce
lipocalin-2.
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Several researchers have studied the effects of delivering
genetically modified macrophages to injured tissue, focusing
primarily on the use of anti-inflammatory cytokines for
therapeutic purposes.1–3 Wilson et al.2 developed a system
of locally introduced bone marrow–derived macrophages
(BMDM) into inflamed glomeruli during nephrotoxic
nephritis.2 In this system, they were able to demonstrate
that the injection of interleukin (IL)-10–overexpressing
macrophages reduced glomerular inflammation. Despite the
confirmed therapeutic role of IL-10 therapy in these renal
diseases, it remains unclear whether this therapy may also
prove to be effective in renal ischemia/reperfusion injury
(IRI). We previously highlighted that macrophages have a
critical role in IRI,4 indicating that renal repair and
inflammation are closely interlinked. We demonstrated that
macrophages fostered regeneration under anti-inflammatory
conditions, but were unable to exert this pro-reparative effect
in an inflammatory environment. In view of these findings,
we overexpressed IL-10 in BMDMs and adoptively trans-
ferred them to ischemic kidneys during the inflammatory
phase with the aim of testing whether these predominantly
anti-inflammatory macrophages were able to modulate
inflammation and injury.
Lipocalin-2 (Lcn-2) is a 25-kDa protein substantially
upregulated following renal tubular injury and may have a
role in limiting kidney damage.5,6 Recent evidence suggests
that Lcn-2 functions as a growth and differentiation factor in
multiple7 cells. Application of exogenous Lcn-2 to epithelial
cells induced proliferation and expression of genetic markers
of early epithelial progenitors. Some of the biological effects
of Lcn-2 may depend markedly on its association with the
iron complex. It has also been shown that Lcn-2 may induce
apoptosis as a result of depletion of intracellular iron pools.
This effect, however, is abolished if iron-loaded Lcn-2 is
used.8 What is of great significance is that it appears to be the
presence of iron that accounts for the distinct biological
effects of Lcn-2. Furthermore, Lcn-2 was recently described as
being regulated by iron.9
In vivo evidence has outlined the role of IL-10 in
enhancing intracellular iron10 and also inducing the
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expression of heme oxygenase (HO),11 leading to excessive
heme degradation and the resultant increase in iron. In
addition, previous studies revealed profound effects of anti-
inflammatory cytokines on iron homeostasis.12
Considering that intracellular iron is a biological response
of IL-10 and an inducer of the synthesis of the potentially
pro-reparative Lcn-2, we hypothesized that macrophages
overexpressing IL-10 exert their reparative function by means
of an increase in intracellular iron and its action upon Lcn-2.
RESULTS
Maturity and specificity of BMDMs
We determined the mature macrophage marker CD11b on
the surface of BMDMs by flow cytometry. Results showed
a differentiation rate of about 80% (CD11b-positive cells
in %: isotype 1.32±0.42; CD11b 82.44±5.41). In addition,
BMDMs were stained for the mature macrophage marker
ED1. Immunofluorescence showed a high expression profile
of nearly 100% of total BMDMs (Figure 1).
IL-10 macrophages protect against IRI
Blood urea nitrogen (BUN; Figure 2a) and creatinine (Figure
2b) showed an increase after IRI. Administration of control
macrophages was unable to prevent injury, whereas IL-10
macrophages significantly reduced creatinine levels up to
control levels. In addition, BUN levels were substantially
diminished, but still remained higher than the control group.
Histological analysis (Figure 2c and d) indicated that renal
injury could be observed at 24 h of reperfusion. Treatment
with IL-10 macrophages showed significantly higher tissue
integrity, whereas transfer of control macrophages did not
improve injury. Tissue injury was significantly decreased with
respect to the I/R_b-gal group, but was still significantly
higher than sham animals. Thus, IL-10–overexpressing
BMDMs were highly protective against injury, but still higher
cell doses might be needed to achieve the complete reversion
to control levels.
Transduction efficiency was evaluated via adenovirus GFP,
with adenovirus IL-10 macrophages showing dose- and time-
dependent increases in IL-10 expression. We also measured
mannose receptor, IL-1b, and nitric oxide production.
Results show an upregulation of anti-inflammatory mediators
in IL-10 macrophages, even when stimulated with lipopoly-
saccharides (Supplementary Figure S1 online). This may also
occur because of autocrine effects of IL-10 itself, as IL-10 is
known to be able to polarize macrophages toward an anti-
inflammatory M2 phenotype.
TNF-a and IL-1b expression was reduced upon admin-
istration of IL-10 macrophages (Figure 3a), whereas the anti-
inflammatory mediator profile was increased in the ischemic
kidney (Figure 3b).
Ki-67 and proliferation cellular nuclear antigen (PCNA)
(Figure 3c) showed a clear increase in the IL-10 macrophage-
treated groups. We performed staining for PCNA and
stathmin13–15 as known regenerative markers. Few cells were
found to express stathmin and PCNA under sham conditions
or in ischemia/reperfusion (I/R) group (Figure 3d). Treat-
ment with control macrophages showed similar results,
whereas IL-10 macrophages increased their expression.
Importantly, BMDMs localized efficiently to injured renal
tissue, indicated by PKH-26GL staining of infused macro-
phages (Supplementary Figure S2 online).
IL-10 macrophages induce Lcn-2
Levels of Lcn-2 mRNA (Figure 4a), protein (Figure 4b),
receptor Lcn-2 mRNA (Figure 4c), and megalin mRNA
expression (Figure 4d) were measured and showed significant
increase in all ischemia/reperfusion groups, although these
levels were further increased following treatment with IL-
10–overexpressing macrophages but not with untransduced
macrophages (e.g., up to threefold for Lcn-2 protein
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Figure 1 |Maturity of bone marrow–derived macrophages.
(a) The assessment of CD11b levels by flow cytometry
demonstrates clear maturity and differentiation of precursor cells
from the bone marrow toward macrophages after incubation with
granulocyte-macrophage colony-stimulating factor (10 ng/ml) for
7 days (CD11b-positive cells in %: isotype 1.32±0.42; CD11b
82.44±5.41). (b) Immunofluorescent staining of ED1 (CD 68) of
bone marrow–derived macrophages showed high numbers of
ED1-positive cells out of the total number of cells differentiated
from whole bone marrow preparations, thus confirming the
maturity status of differentiated macrophages. A representative
cross-section of five independent experiments is illustrated.
FITC, fluorescein isothiocyanate.
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compared with a twofold increase in the I/R group alone or
in the presence of untransduced macrophages). Despite these
results, it is difficult to draw concrete interferences concern-
ing the origin of Lcn-2 at this point as especially the mRNA
data point toward the involvement of other cells in the
production of total Lcn-2 in the kidney.
Table 1 shows the highest range of macrophage density
(ED1-positive cells) in the corticomedullary area of renal
tissue, although significance was not achieved.
We stained for Lcn-2 and macrophages (ED1; Figure 5). In
the I/R group, macrophages infiltrated the kidney, but did
not show co-localization with Lcn-2. When IL-10 macro-
phages were infused, a great number of BMDMs could be
observed co-localizing with Lcn-2, suggesting that Lcn-2 was
produced by the administered BMDMs. This might hold true
because of the fact that IL-10–overexpressing macrophages
were transduced with an adenoviral vector, so that a
continuous production of Lcn-2 was found and detected in
these macrophages. Tubular cells produce Lcn-2, but as it is a
secreted protein released immediately into urine, immuno-
logical detection of Lcn-2 coming from tubular cells is
difficult to achieve by immunohistochemistry. In this sense, it
can only be stated that IL-10 macrophages contribute to the
overall Lcn-2 protein content in the kidney.
Lcn-2 expression was induced in a dose-dependent
manner in vitro. Lcn-2 protein (Figure 6a) from IL-10
macrophages and both Lcn-2 receptors (Figure 6b and c)
showed an increase in line with the transduction of IL-10 to
rat BMDMs. External stimulation with Lcn-2 (80 ng/ml;
Figure 6d) showed a significant upregulation of both Lcn-2
and its receptors. Incubation of BMDMs with green
fluorescent protein (GFP)-tagged Lcn-2 revealed direct
protein–receptor interactions given that the fluorescent signal
was determined on the surface of the cells (Figure 6eB).
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Figure 2 | Interleukin (IL)-10-transduced macrophages protect against ischemia/reperfusion injury. Animals were subjected to 45min
of bilateral ischemia or were sham-operated and killed at 24 h of reperfusion. The effect on (a) blood urea nitrogen (BUN) and (b) creatinine
in plasma of adoptive transfer of either b-gal- or IL-10–treated macrophages was assessed. Macrophage infusion was performed for each
condition at 1 h of reperfusion. The following groups were analyzed: Sham: control group without infusion of macrophages; ischemia/
reperfusion (I/R): 45min of bilateral ischemia followed by 24 h of reperfusion; I/R_MACS: ischemia/reperfusion group with injection of
untreated bone marrow–derived macrophages; I/R_IL-10: ischemia/reperfusion group with adoptive transfer of ex-vivo–modified
macrophages overexpressing IL-10; I/R_b-gal: ischemia/reperfusion group with administered control b-gal-expressing macrophages. Data
are represented as means±s.e.m.; n¼ 5; *Po0.05 vs. Sham, þPo0.01 vs. Sham, yPo0.01 vs. IR_b-gal. (c) Conventional histological analysis
of hematoxylin and eosin-stained kidney sections (original magnification  400) of the corticomedullary region confirmed protective effects
of IL-10 administration compared with Adb-gal-BMDM infusion. Representative images of sham rats are shown and compared with
ischemia/reperfusion groups. (d) Histological damage was quantified in a blinded manner by a skilled expert in the field. *Po0.05 vs. Sham,
þPo0.01 vs. Sham, #Po0.05 vs. IR_b-gal.
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Addition of Lcn-2 without GFP-tag reduced the staining
(Figure 6eC), indicating the ability of Lcn-2 to compete for
its receptor.
Lcn-2 expression from IL-10 BMDMs depends on iron
Cellular iron increased following AdIL-10 transduction,
revealing the iron-retaining role of IL-10. The iron chelator,
desferroxamine (DFO), reduced cellular iron in BMDMs
(Figure 7a). Lcn-2 mRNA expression and Lcn-2 protein
content (Figure 7b and c) showed a significant increase where
cellular iron content was high, thus indicating the likely
function of Lcn-2 as an iron target gene.
Inflammatory markers are modulated by way of the
administration of iron and the iron chelator DFO. Results
indicate an increased expression of anti-inflammatory
markers in the groups with induced Lcn-2 (Supplementary
Figure S3 online).
IL-10 rescues viability via an iron-dependent mechanism
NRK52e cells were subjected to anoxia, and viability was
measured by fluorescence-activated cell sorting via propi-
dium iodide (PI)/annexin V 16 h after treatment with
conditioned media (CM) from differentially stimulated rat
BMDMs. Figure 8a shows a protection of renal epithelial cells
upon the administration of CM from high-iron-content cells
such as IL-10–transduced or Fe-treated macrophages. A
detailed analysis is represented in Figure 8b. Ki-67 and PCNA
mRNA expression showed a pro-proliferative profile. This
evidence was in line with previous results, in that high-iron-
content cells, whether by way of overexpressing IL-10 or
through direct treatment with Fe, released a soluble factor
into the CM capable of rescuing renal epithelial cells from
injury (Figure 8c). The application of CM to a different cell
line revealed the same tendencies (Supplementary Figure S4
online). To underline the role of Lcn-2 in CM, cells were
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Figure 3 | Interleukin (IL)-10-transduced macrophages modify the inflammatory milieu and induce tubular cell proliferation after
ischemic injury in vivo. Animals were subjected to 45min of bilateral ischemia or sham-operated and killed at 24 h of reperfusion, with
macrophage infusion at 1 h of total reperfusion time where indicated. The following groups were analyzed: Sham: control group without
infusion of macrophages; ischemia/reperfusion (I/R): bilateral ischemia of 45min with subsequent reperfusion of 24 h; I/R_MACS: ischemia/
reperfusion group with injection of untreated bone marrow–derived macrophages; I/R_IL-10: ischemia/reperfusion group with adoptive
transfer of ex-vivo–modified macrophages overexpressing IL-10; I/R_b-gal: ischemia/reperfusion group administered control b-gal-
expressing macrophages. (a) Tumor necrosis factor (TNF)-a and IL-1b kidney expression profiles as representative inflammatory milieu and
(b) IL-10 and IL-4 expression profiles as representative anti-inflammatory milieu of the different study groups was measured by mRNA
expression via reverse transcription (RT)-PCR. Results show the downregulation of pro-inflammatory milieu via the adoptive transfer of IL-
10–overexpressing macrophages, indicating a crucial role for IL-10 in macrophage phenotype determination and inflammation outcome.
(c) The effect of Ki-67 and proliferation cellular nuclear antigen (PCNA) mRNA expression (tested via quantitative RT-PCR in total renal tissue
homogenates) and (d) immunostaining of stathmin (green) and PCNA (red) expression (original magnification  400), in renal tissue of
adoptive transfer of either b-gal- or IL-10–treated macrophages, was assessed. Results show a clear increase of regenerative/proliferative
parameters in the IL-10 macrophage-treated groups, thereby indicating the pro-proliferative effect of IL-10 macrophages in kidney repair.
Real-time PCR data were normalized to the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed as
arbitrary units of relative expression. Data are represented as means±s.e.m; n¼ 5; *Po0.05 vs. Sham, þPo0.01 vs. Sham, yPo0.01 vs. IR_b-gal.
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tested with CM in the presence of Lcn-2–neutralizing
antibody or control IgG antibody (Table 2). Results showed
a decrease in viability upon blockage of Lcn-2 in CM.
IL-10 rescues from IRI via iron and Lcn-2
BUN (Figure 9a) and creatinine (Figure 9b) indicated an
essential role for iron and Lcn-2 in IL-10 protection. Lcn-2
blockade or DFO treatment in IL-10 macrophages caused an
increase in both markers. Hematoxylin and eosin staining
(Figure 9c) and histological analysis (Table 3) further
corroborated these results. Pro- (Figure 9d) and anti-
inflammatory (Figure 9e) cytokine profiles showed an
upregulation of inflammation in IL-10–treated animals when
Lcn-2 was either blocked or was in the group in which DFO-
treated, IL-10–transduced macrophages were infused. Such
observations highlighted the crucial roles for Lcn-2 and iron
on IL-10 therapy (Figure 9f). Ki-67 and PCNA indicate that
Lcn-2 blockade abolished IL-10–dependent protective effects.
DFO data support previous evidence. Further immunostain-
ing for PCNA and stathmin corroborated the expression data
(Figure 9g).
To study the actions specific to anti-Lcn-2, incubation
with an isotype-matched IgG antibody was performed.
Results revealed the role of anti-Lcn-2 in reducing both
Lcn-2 and its receptors in vitro. Incubation with anti-IgG had
no effect on the expression of Lcn-2 and its receptors, thus
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Figure 4 |Adoptive transfer of interleukin (IL)-10 macrophages modulates lipocalin-2 expression, the tissue receptor lipocalin-2,
and megalin expression in ischemic kidneys in vivo. Macrophages were infused, where indicated, at 1 h of total reperfusion time (24 h)
following 45min of bilateral ischemia. The following experimental groups were included in the study: Sham: control group without infusion
of macrophages; ischemia/reperfusion (I/R): bilateral ischemia for 45min followed by 24 h of reperfusion; I/R_MACS: ischemia/reperfusion
group with injection of untreated, bone marrow–derived macrophages; I/R_IL-10: ischemia/reperfusion group with adoptive transfer
of ex-vivo–modified macrophages overexpressing IL-10; I/R_b-gal: ischemia/reperfusion group administered control b-gal-expressing
macrophages. (a) Lipocalin-2 mRNA levels, (b) lipocalin-2 protein, and (c) receptor lipocalin-2 mRNA and (d) megalin mRNA expression were
measured, and showed a significant increase in all ischemia/reperfusion groups, although fold induction after treatment with IL-
10–overexpressing macrophages was even higher than that with untransduced macrophages. Real-time reverse transcription PCR data were
normalized to relative expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and presented as
arbitrary units of relative expression. ELISA data were expressed as nanogram per milligram of protein. Data are represented as
means±s.e.m.; n¼ 5, þPo0.01 vs. Sham, yPo0.01 vs. IR_b-gal.
Table 1 | Quantification of ED1-positive macrophages in renal kidney sections
Sham I/R I/R_IL-10 I/R_b-gal
Macrophage density, counts/ 400 field (ED1-positive cells) 2–8 50–120 80–150 70–130
Abbreviations: I/R, ischemia/reperfusion; IL, interleukin.
The effect of the different treatments with adoptive transfer of ex-vivo–modified macrophages on interstitial macrophage infiltration in renal ischemia reperfusion injury
outcome was evaluated by quantification of ED1-positive macrophages in the corticomedullary area of renal tissue sections. Positive cells were counted from eight different
fields per sample, averaged, and expressed as a range of macrophage density.
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indicating the specific activity of the neutralizing antibody
(Supplementary Figure S5 online). In addition, in order to
show that DFO treatment does not affect the viability of the
macrophages, control macrophages were treated with DFO
with and without iron. As shown in Supplementary
Figure S6, cell viability measured by Hoechst/PI remained
unaffected by any of the treatments. However, when iron was
added after treatment with the chelator, both Lcn-2 and iron
levels were recovered (Supplementary Figure S6 online).
DISCUSSION
Previous work of our group indicated that macrophages were
able to promote repair under anti-inflammatory conditions.4
This previous study revealed that the administration of
resting macrophages was unable to induce regeneration at the
time points in which tissue was inflamed, and were only able
to promote regeneration when macrophages were reinjected
during the period of no inflammation (at 72 h of reperfu-
sion). We concluded that macrophages induce renal regen-
eration after ischemia/reperfusion, but that this function
depends on the inflammatory milieu. Recently, the biphasic
effect of macrophages in the injured kidney has been
observed and attributed to a macrophage switch toward an
alternatively activated macrophage phenotype, leading to the
suppression of the inflammatory response and promotion of
a proliferative repair phase.16 Furthermore, it has been
suggested that the targeting of macrophage activation and
phenotype is leading to new therapies in the treatment of
many acute and chronic kidney diseases.17
Results of the present study reinforce these findings, as
administration of untreated macrophages during the inflam-
matory phase did not influence repair. We report here that
IL-10–overexpressing macrophages are effective during the
inflammatory phase, but it should still be noted that probably
higher cell doses would be needed to achieve full protection.
Although it may be evident that these macrophages give rise
to anti-inflammation, they also foster the expression of pro-
regenerative factors such as Lcn-2. Administration of IL-10
macrophages augments repair owing to the fact that (1) they
are primed toward M2 and (2) are able to reprogram the
inflammatory environment. Alternatively, they might be able
to reprogram resident macrophages toward M2, but this has
not been demonstrated in the present study. The clinical use
of IL-10 has been studied in a great variety of inflammatory
and infectious disorders,18 and alterations in the production
of IL-10 have been linked to numerous disease states.19–22
With regard to the kidney, Huang et al.23 reported that IL-10
inhibits macrophage-mediated glomerular injury, including
the reduction of proteinuria, histological severity, and the
production of pro-inflammatory cytokines. IL-10 has also
been reported to reduce inflammation and mesangial cell
proliferation in acute glomerulonephritis induced by anti-
Thy-1 antibody.24 In addition, it has been observed to
suppress glomerulosclerosis formation in FGS/Kist, a rat
model of spontaneous focal segmental glomerulosclerosis.25
IL-10 administration in animal models for nephrotoxic
nephritis underlined the protective effects of IL-10. Interest-
ingly, gene knockout models for IL-10 in nephritic mice
confirmed an increased glomerular injury profile compared
with wild-type mice.26 In addition, IL-10 administration
significantly reduced ischemia-associated renal injury and
dysfunction, indicated by renal function markers and
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I/R_β-gal I/R_β-gal
Sham
Figure 5 | Immunohistochemical staining for lipocalin-2 (right
panel) and macrophages (ED1; left panel) in renal tissue
sections. Immunohistochemical staining for lipocalin-2 (right
panel) and macrophages (ED1; left panel) in renal tissue sections
of the different study groups revealed the source of lipocalin-2
in vivo. In the ischemia/reperfusion (I/R) group, a great number of
macrophages infiltrated the inflamed/injured kidney, but did not
co-localize with lipocalin-2 expression. On the contrary, when
interleukin (IL)-10-transduced macrophages were infused at
1 h of total reperfusion time, there was a significant number
of co-localized macrophages, plus increased lipocalin-2
immunoreactivity, indicating lipocalin-2 production by the
macrophages administered. Evaluation was performed with light
microscopy (original magnification  40). Microphotographs
show representative images of five independent experiments for
each condition.
974 Kidney International (2012) 81, 969–982
or ig ina l a r t i c l e M Jung et al.: IL-10 cell therapy, iron, and Lcn-2
histological analysis.27 The fact that IL-10 may inhibit
ischemia-associated renal injury is of relevant clinical
importance as ischemia is one of the major causes of acute
renal failure following renal transplantation. Nevertheless,
data from unbiased searches for urinary molecules in humans
revealed that the presence of IL-10 is not a relevant factor in
kidney injury in humans, owing to the fact that IL-10 was not
upregulated in patients with acute postoperative kidney
injury28 compared with those without. In addition, BMDMs
genetically modified to produce IL-10 reduced injury in
experimental glomerulonephritis.2
However, the therapeutic role of IL-10 macrophages in IRI
had not been addressed until now. Consequently, there are
mechanisms and mediators that are yet to be elucidated.
One possible regenerative mediator is Lcn-2, which is
produced at sites of injury and may act by modulating
repair.29,30 We were able to verify that the administration of
IL-10 macrophages induces Lcn-2 and its receptors in the
kidney. In addition, we found that increases in renal Lcn-2,
produced as a consequence of IL-10 therapy, were mainly due
to the infiltration of macrophages, as observed by co-
localization. Sheng et al. demonstrated that the regulation of
Lcn-2 and its receptor is mediated through distinct
transcription and signaling pathways, which may act
simultaneously.31 The beneficial effects of IL-10 therapy
could be attributed to increases in Lcn-2 release and function,
which could be inferred by the action of Lcn-2 on its
receptors. Lcn-2 activation of its receptors could be able to
increase Lcn-2 uptake, thereby favoring its reparative
functions in renal epithelial cells. It could be suggested that
Lcn-2 activities are similar to those of growth factors7 capable
of modulating various cellular responses, including apopto-
sis, proliferation, and differentiation. The administration
of Lcn-2–neutralizing antibodies reversed IL-10–mediated
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Figure 6 | Lipocalin-2 (Lcn-2) and its receptors are synthesized from adenovirus IL-10 (AdIL-10)–transduced, rat bone
marrow–derived macrophages in a dose-dependent manner in vitro. (a) Lcn-2 protein content was measured by ELISA from cellular
supernatant of AdIL-10–transduced primary macrophages. mRNA levels of both Lcn-2 receptors, megalin (b), and receptor Lcn-2 (c) were
measured by real-time reverse transcription (RT) PCR, and showed a significant increase in a dose-dependent manner, which was in line with
the transduction of IL-10 to rat bone marrow–derived macrophages. (d) External stimulation of rat bone marrow–derived macrophages with
recombinant Lcn-2 protein (80 ng/ml) for a 24-h period showed a significant upregulation of both Lcn-2 and its receptors, measured by real-
time RT-PCR. Such is indicative of a positive feedback mechanism of Lcn-2 in and of itself along with its receptors. (e) Bone marrow–derived
macrophages (A) were incubated with 5 mg of green fluorescent protein (GFP)-tagged recombinant Lcn-2 protein for 24 h (B) or with
recombinant Lcn-2 protein without GFP-tag (50 mg) for competitive analysis (C). GFP staining can be observed surrounding the cells,
resulting in a marked increase in staining after incubation with the GFP-tagged recombinant Lcn-2 protein alone, unlike the case of the
competitive test (C). Cells were viewed on a Leica TCS NT laser microscope. Magnification  40; n¼ 5. Real-time RT-PCR data were
normalized to relative expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and were presented as
arbitrary units of relative expression. ELISA data were expressed as nanogram per milligram protein. Data are represented as means±s.e.m.
from macrophages isolated from four different rats. Each femur was used separately and evaluated at least in triplicate for each group;
*Po0.05 vs. IL-10_0/unstimulated; þPo0.01 vs. IL-10_0/unstimulated.
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protection against IRI, indicating that the protective effects
may depend to some extent on the production of Lcn-2.
Tilg et al.10 provided evidence for the involvement of IL-
10 in anemia during inflammatory diseases. A direct effect of
IL-10 on ferritin translation and the storage of iron within
macrophages was described.
Iron accumulation could be attributed to the induction of
HO, described in previous studies,11 which indicated that IL-
10 induces expression of HO-1, a stress-inducible protein
with potential anti-inflammatory effect, via a p38 mitogen-
activated protein in murine macrophages. HO-1 induction
via IL-10 could lead to excessive heme degradation and,
consequently, increases in iron. In addition, the administra-
tion of genetically modified macrophages overexpressing
HO-1 has been proven effective in improving the outcomes
in kidney ischemia/reperfusion.32
Our results are consistent with these observations, given
the fact that the increase in cellular iron after AdIL-10
transduction elucidates the role of IL-10 to accumulate iron.
The highly specific iron chelator DFO33 provokes a decrease
in intracellular iron when administered to IL-10 macrophages
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Figure 7 | Lipocalin-2 (Lcn-2) expression from interleukin (IL)-
10-transduced, rat bone marrow–derived macrophages is
dependent on cellular iron content. (a) Transduced rat
bone marrow–derived macrophages were incubated with
desferroxamine (DFO; 100 mmol/l) for 24 h. Macrophage control
groups included treatment with iron (20mg/ml), untreated
macrophages, and b-gal-transduced macrophages. Cellular iron
content shows a significant increase after treatment with iron and
after adenovirus IL-10 (AdIL-10) transduction, indicating the iron-
retaining role of IL-10. The iron chelator DFO significantly reduced
cellular iron content. (b) Lcn-2 mRNA expression and (c) Lcn-2
protein content was measured in these groups and showed a
significant increase where cellular iron content was high, thus
indicating the likely function of Lcn-2 as an iron target gene. Real-
time reverse transcription PCR data were normalized to relative
expression of the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and were presented as arbitrary units of
relative expression. ELISA data were expressed as nanogram per
milligram protein. Data are represented as means±s.e.m. from
macrophages isolated from four different rats; each femur was
used separately and evaluated at least in triplicate for each group,
*Po0.01 vs. Control, yPo0.01 vs. IL10.
Figure 8 | Interleukin (IL)-10 rescues renal epithelial cell viability from anoxic injury in vitro via an iron-dependent mechanism.
(a) Fluorescence-activated cell sorting analysis of propidium iodide (PI) binding and annexin V binding of renal epithelial cells 16 h after
treatment with conditioned media from differentially stimulated rat bone marrow–derived macrophages under anoxic conditions. The plots
indicate the proportion of live, viable cells (annexin V-negative, PI-negative), early apoptotic cells (annexin V-positive, PI-negative), necrotic
cells (annexin V-negative, PI-positive), and dying cells (annexin V-positive, PI-positive). Untreated control cells were treated with equal
volume of diluent (binding buffer) without staining. Experiments were conducted in triplicate in five independent experimental settings.
Results show a clear protection of renal epithelial cells upon the administration of conditioned media from high-iron-content cells such as
IL-10–transduced or Fe-treated macrophages. (b) The proportion of viable cells, early apoptotic cells, necrotic cells, and dying cells is
represented in the table as percentages of the total cell number. Untreated control cells were treated with an equal volume of diluent
without any staining. Experiments were conducted in triplicate in five independent experimental settings and represented as means±s.e.m.
#Po0.05 vs. CM normoxia, *Po0.05 vs. CM anoxia, þPo0.01 vs. CM anoxia. The effect of conditioned media upon (c) Ki-67 and proliferation
cellular nuclear antigen (PCNA) mRNA expression, assessed through quantitative reverse transcription (RT) PCR in total renal cell
homogenates, showed a pro-proliferative profile. This evidence was in line with previous results, in that high-iron-content cells, be it by way
of overexpressing IL-10 or through direct treatment with Fe, release a soluble factor into the conditioned media capable of rescuing renal
epithelial cells from injury. Real-time RT-PCR data were normalized to relative expression of the housekeeping gene glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and were presented as arbitrary units of relative expression. Data are represented as means±s.e.m.;
n¼ 8, *Po0.05 vs. CM IL-10, #Po0.01 vs. CM IL-10; yPo0.01 vs. Control anoxia.
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in line with a decrease in Lcn-2 expression, indicating a direct
link between IL-10, iron accumulation, and Lcn-2 induction.
Our results corroborate previous reports that Lcn-2 is
regulated by iron. It could be concluded that the biological
effects of IL-10 are dependent on iron, and thus the
expression of Lcn-2. The role of iron as an inducer of Lcn-
2 is consistent with previous studies that have indicated that
the presence of iron appears to account for the distinct
biological effects of Lcn-2.8 Furthermore, a secondary effect
of Lcn-2 on iron accumulation cannot be discarded, as it is
known that Lcn-2 could bind to iron and deliver it to the cell
through a process requiring endocytosis by a pathway
differing from that used by transferring.34
In conclusion, the adoptive transfer of IL-10 macrophages
to ischemic kidneys protects against acute kidney injury. The
protection is mediated through the action of IL-10 on
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intracellular iron, which is able to induce Lcn-2, and in turn
act as a mediator of the beneficial effects of IL-10 therapy.
MATERIALS AND METHODS
Animal model
The study was conducted using male Sprague–Dawley rats (Charles
River, Wilmington, MA). Experiments were conducted with the
approval of our institution’s Research Commission, and by
following European Union guidelines for handling and care of
laboratory animals. Animals were anesthetized with isolfurane and
placed in a supine position with body temperature maintained at
37 1C. The abdominal area was covered to minimize dehydration.
After laparotomy and dissection of renal pedicles, bilateral
ischemia was induced by occluding the renal pedicles with an
atraumatic microvascular clamp for 45min. During reperfusion, the
clamps were removed.
Experimental groups (n¼ 5 per group)
Sham: control without infusion of macrophages; I/R: 45min of
bilateral ischemia followed by 24 h of reperfusion; I/R _MACS: I/R
group with injection of untreated BMDMs; I/R_b-gal: I/R group
injecting b-gal macrophages; IL-10: I/R group with adoptive transfer
of BMDMs overexpressing IL-10; IL-10þAbLcn-2: after 45min
ischemia, following 50min of reperfusion, a neutralizing anti-Lcn-2
(75mg per animal) antibody was administered intravenously. At 1 h
of reperfusion, IL-10 macrophages were transferred; IL-10þAbIgG:
as in the previous group, but using anti-IgG (75 mg per animal)
isotype control antibody; IL-10þDFO: IL-10 macrophages were
treated ex vivo with DFO (Sigma, Madrid, Spain; 100 mmol/l) for
24 h; DFO-treated IL-10 macrophages were then injected intrave-
nously at 1 h of reperfusion; AbLcn-2: bilateral ischemia was
induced for 45min. At 1 h of reperfusion, a neutralizing anti-Lcn-2
antibody (75 mg per animal) was injected intravenously without
the additional transfer of macrophages; total reperfusion time
was 24 h.
At 24 h of reperfusion, kidneys were harvested and snap-frozen at
80 1C, set in paraformaldehyde or embedded in an optical
coherence tomograph and frozen in liquid nitrogen. Animals were
killed and blood was collected.
Isolation, culture, and transfer of rat BMDMs
Rat BMDMs were isolated from the femur and matured in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum, 10 ng/ml granulocyte-macrophage colony-stimulat-
ing factor, 100U/ml penicillin, and 100mg/ml streptomycin for
7 days. For in vivo studies, BMDMs were transduced with adenoviral
vectors to enable the expression of either IL-10 or b-gal. Where
indicated, ex-vivo–stimulated BMDMs (1 106 cells per animal)
were injected intravenously by puncture to the inferior cava at 1 h of
reperfusion. BMDMs were tagged with the red fluorescent
membrane label PKH-26GL (Sigma) in order to check their
localization.35
Generation of CM from BMDMs
To obtain CM, macrophages were cultured in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum, 100U/ml
penicillin, and 100mg/ml streptomycin. After transduction, BMDMs
were starved for 24 h before the collection of CM. Supernatants from
treated BMDMs were harvested via centrifugation and filtration
through 0.2 mm pore filters.
Adenoviral vectors
Adenoviral vectors (AdIL-10, Adb-gal, and adenovirus GFP) were
kindly provided by Dr David Kluth and Dr Jeremy Hughes (MRC-
CIR, Edinburgh, UK). For dose–response assays, 1 106 cells were
transduced at different doses. An optimum multiplicity of infection
of 50 was used for all experiments.
Caspase-3 activity assay
Caspase-3 activity was determined by measuring proteolytic
cleavage of the substrate N-acetyl-Asp-Glu-Val-Asp-7-amino-4-
methylcoumarin (Biomol, Lausen, Switzerland). A measure of
250 mg of protein and 12mmol/l N-acetyl-Asp-Glu-Val-Asp-7-
amino-4-methylcoumarin was used to perform the assay, quantify-
ing released amino-4-methylcoumarin by fluorospectrophotometry.
Griess assay
Nitrite accumulation was determined using the Griess reaction
(Promega, Madison, WI) according to manufacturer’s instructions.
Stimulation of BMDM
Rat BMDMs were incubated either with Lcn-2–neutralizing anti-
body (10 mg/ml; R&D, Minneapolis, MN) or with the isotype-
matching IgG antibody (10 mg/ml; R&D) for 24 h. Transduced
BMDMs were then incubated with lipopolysaccharides (15 ng/ml;
Sigma) for 24h. For Lcn-2-receptor studies, BMDMs were incubated
with GFP-tagged Lcn-2 (5 mg/ml) for 24 h in the presence or absence
of the competing Lcn-2 (50 mg/ml) without GFP-tag. Both recom-
binant proteins were supplied by PROTERA (Florence, Italy).
Iron determination
BMDMs were incubated with DFO (100 mmol/l) for 24 h. Control
groups comprised treatment with iron (FERIV, G.E.S. GENERICOS
ESPAN˜OLES LABORATORIO, S.A., Madrid, Spain; 20mg/ml),
untreated cells, and b-gal-BMDM. Iron content was measured using
Table 2 | Renal epithelial cell viability after anoxic injury in vitro is dependent on lipocalin-2 in CM from IL-10 macrophages
CM IL-10 CM IL-10+AbLcn-2 CM IL-10+AbIgG CM b-gal CM b-gal+AbLcn-2
% Viable cells 98.3±2.28 49.04±7.32* 95.13±0.15 48.81±2.76* 46.41±2.78*
Abbreviations: CM, conditioned media; IL, interleukin; Lcn-2, lipocalin-2.
Trypan blue exclusion assay on NRK 52e cells incubated with conditioned media from adenovirus IL-10 (AdIL-10)–transduced macrophages under anoxic conditions. Cells
were tested with conditioned media in the presence of either a lipocalin-2-neutralizing antibody or the isotype-matching control IgG antibody. Results confirm lipocalin-
2–dependent rescue from anoxia-induced injury, and hence loss of viability, suggesting a key role of lipocalin-2 in protection. In contrast, treatment of renal epithelial cells
with conditioned medium from Adb-gal-transduced macrophages could not restore viability of renal epithelial cells under anoxic conditions. The presence or absence of a
specific lipocalin-2-neutralizing antibody did not have any effect upon Adb-gal-transduced macrophages, implying a link of IL-10 and lipocalin-2 in macrophages. Viability was
measured in triplicate of five independent experiments. *Po0.01 vs. CM IL-10.
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Figure 9 | Interleukin (IL)-10 rescues cell viability from ischemic injury in vivo via an iron- and lipocalin-2-dependent mechanism.
Animals were subjected to 45min of bilateral ischemia and were subsequently infused, where indicated, with previously stimulated bone
marrow–derived macrophages at 1 h of total reperfusion time. Animals were killed at 24h of reperfusion. The following study groups were
analyzed: ischemia/reperfusion (I/R): bilateral ischemia of 45min with subsequent reperfusion of 24h; IL-10: ischemia/reperfusion group with
adoptive transfer of ex-vivo–modified macrophages overexpressing IL-10; IL-10þAbLcn-2: a neutralizing lipocalin-2 antibody (75mg per animal)
was administered intravenously to the ischemia/reperfusion group 10min before IL-10–expressing macrophage transplantation; IL-10þ _AbIgG: a
rat IgG antibody (75mg per animal) was administered intravenously to the ischemia/reperfusion group 10min before IL-10–expressing
macrophage infusion; IL-10þDFO: ex-vivo–modified macrophages overexpressing IL-10 were treated with the iron chelator deferoxamine (DFO;
dose used: 100mmol/l) before intravenous administration to the ischemia/reperfusion group; AbLcn-2: to evaluate the effect of the neutralizing
lipocalin-2 antibody (75mg per animal) on the injury outcome, 75mg per animal was administered intravenously at 1h of total reperfusion time
(24h) to the ischemia/reperfusion group. (a) Blood urea nitrogen and (b) creatinine in plasma clearly revealed a key role of lipocalin-2 expression
in IL-10–mediated protection from injury. (c) Conventional histological analysis of hematoxylin and eosin-stained kidney sections (original
magnification  400) of the corticomedullary region corroborated the importance of iron-dependent lipocalin-2 expression in IL-10 therapy with
regard to protection from ischemia/reperfusion injury. (d) Pro-inflammatory and (e) anti-inflammatory cytokine profiles of the different study
groups highlighted the upregulation of pro-inflammatory milieu upon lipocalin-2 blockage with the neutralizing antibody, indicating a crucial
role for lipocalin-2 in IL-10–mediated inflammation outcome. Data from the group in which DFO-treated, IL-10–transduced macrophages were
infused confirm the in vitro data as pertaining to the function of IL-10–iron–lipocalin-2 in relation with protection against ischemia/reperfusion-
associated kidney damage. (f) Pattern of normalized Ki-67 and proliferation cellular nuclear antigen (PCNA) mRNA expression evaluated via
quantitative reverse transcription PCR indicates that lipocalin-2 has an important role in kidney repair following ischemia/reperfusion injury, given
the fact that blockage of lipocalin-2 by its neutralizing antibody completely abolished IL-10–dependent protective and pro-proliferative effects
on damaged renal tissue. DFO data supported previous data addressing the importance of iron in the expression of lipocalin-2 from
IL-10–transduced macrophages and their associated protective effects on damaged kidney epithelia. PCR data were normalized to the
housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and were represented as arbitrary units of relative expression.
(g) Immunofluorescent staining of the regeneration markers PCNA (red) and stathmin (green) further confirmed PCR data and underlined the
role of the IL-10/iron/lipocalin-2 axis in renal ischemia/reperfusion injury. Data are represented as means±s.e.m.; n¼ 5; þPo0.01 vs. I/R_IL-10.
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an ADVIA 2400 (Siemens Medical Diagnostics, Deerfield, IL)
multichannel analyzer.
Anoxia experiments
Rat renal epithelial NRK52e cells and human embryonic kidney cells
(HEK 293; ECACC, Salisbury, UK) were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal bovine
serum, 100U/ml penicillin, and 100mg/ml streptomycin. Cells were
subjected to anoxic (0.5% O2) or normoxic conditions (20.7% O2)
for 16 h in the presence of either an Lcn-2–neutralizing antibody or
an IgG isotype–matched antibody. Where indicated, cells were
treated with CM from BMDMs.
Trypan blue assay
Cells were incubated with 0.2% Trypan blue (Sigma) in phosphate-
buffered saline for 2min at room temperature. After the reaction,
Trypan blue solution was removed and both viable and dying cells
were counted.
Annexin V/PI flow cytometry
Annexin V (Invitrogen, Grand Island, NY) staining was performed
for 5min. Cells were then centrifuged, resuspended, and incubated
with PI for 5min before taking measurement using a Becton Coulter
flow cytometer (Becton Coulter, Fullerton, CA). Appropriate
internal controls were performed for each experiment.
Hoechst/PI analysis
Cells were incubated with 0.1 mg/ml Hoechst 33342 (Invitrogen) and
1 mg/ml PI (Invitrogen) for 5min at room temperature and analyzed
using a fluorescence microscope.
Renal injury markers
BUN and creatinine were analyzed in plasma using an ADVIA 2400
(Siemens Medical Diagnostics) multichannel analyzer.
Histological analysis
Samples were embedded in paraffin, cut into 4 mm sections, and
stained with hematoxylin and eosin.
Immunofluorescent staining of kidney sections
Kidney sections were unmasked in sodium citrate buffer and
blocked for 1 h. Staining of stathmin and PCNA was carried out as
previously described.15 Slides were incubated with anti-stathmin
(Calbiochem, Darmstadt, Germany) and anti-PCNA antibody (Santa
Cruz, Santa Cruz, CA), followed by incubation with secondary anti-
bodies (Molecular Probes, Eugene, OR) for 2 h. Sections were viewed
using a Leica TCS NT laser microscope (Leica, Wetzlar, Germany).
Immunohistochemistry ED1/Lcn-2
Slides were incubated with anti-ED1 (Serotec, Oxford, UK) and
anti-Lcn-2 (R&D). Sections were stained with secondary antibodies
Table 3 | Histological analysis of hematoxylin and eosin-stained kidney sections
Epithelial necrosis Epithelial balloonization Tubular dilatation Detachment Edema Total score
I/R-IL-10 0.6±0.03 0.4±0.03 0 0.5±0.03 0 1.4±0.02
I/R_IL-10_AbLcn-2 2±0.1+ 1.3±0.04 0.8±0.2 2.9±0.4+ 0.1±0.03 8.2±0.2+
I/R_IL-10_AbIgG 0.3±0.05 0.2±0.1 0 0.1±0.01 0 0.8±0.08
I/R_IL-10_DFO 2.3±0.3+ 0.6±0.07 0.6±0.2 2.4±0.3+ 0.4±0.03 7±0.2+
I/R _AbLcn-2 1.8±0.6+ 0.9±0.08 1±0.5 2.3±0.06+ 0.6±0.06 7.8±0.4+
Abbreviations: DFO, desferroxamine; I/R, ischemia/reperfusion; IL, interleukin.
Histological analysis indicated that animals treated with IL-10–overexpressing macrophages showed significantly higher tissue integrity, whereas adoptive transfer of IL-
10–transduced macrophages in presence of the lipocalin-2-neutralizing antibody lost their protective effect upon ischemia-induced renal injury. Cellular infiltration, tubular cell
balloonization, and severe necrosis could be observed. Furthermore, the transfer of IL-10–transduced macrophages previously treated with the iron chelator DFO did not improve
injury outcome- thus suggesting a key role of iron-induced lipocalin-2 expression in IL-10–mediated protection in renal ischemia/reperfusion injury. +Po0.01 vs. I/R_IL-10.
Table 4 | Primer sequences
Gene (accession number) Source Primer sequence
Annealing
Temperature (1C)
Amp
length (bp)
Rn_Lcn-2 (NM_008491) Invitrogen Forward: 50-CAAGTGGCCGACACTGACTA-30
Reverse: 50-GGTGGGAACAGAGAAAACGA-30
48 192
Rn_GAPDH (NM_017008) Invitrogen Forward: 50-CCGCCAATGTATCCG-TTG-TG- 30
Reverse: 50-TAGCCCAGGATGCCCTTTAGT-30
48 207
Rn_Ki-67 (XM_00105622) Invitrogen Forward: 50-AGACGTGACTGGTTCCCAAC-30
Reverse: 50-ACTGCTTCCCGAGAACTGAA-30
48 197
Rn_PCNA (NM_022381) Invitrogen Forward: 50-AGGACGGGGTGAAGTTTTCT-30
Reverse: 50-CAGTGGAGTGGCTTTTGTGA-30
50 113
Rn_Mannose receptor (NM_001061231) Invitrogen Forward: 50-CGAGGTGGTTTATGGGATGT-30
Reverse: 50-GGGTTCAGGAGTTGTTGTGG-30
50 111
Rn_TNF-a (NM_012675) Invitrogen Forward: 50-AACTCCGACAGCAAGCA-30
Reverse: 50-CGAGCAGGAATGAGAAGAGG-30
55 211
Rn_IL-10 (NM_012854) Qiagen Quantitect primer assay 50 69
Rn_IL-1b (NM_031512) Qiagen Quantitect primer assay 48 91
Mm_IL-4 (NM_021283) Qiagen Quantitect primer assay 50 104
Mm_Megalin (001081088) Qiagen Quantitect primer assay 50 84
Rn_Lcn-2 receptor (NM_177421) Qiagen Quantitect primer assay 48 105
Sequences, annealing temperature, and expected fragment sizes of primers used in real-time quantitative reverse transcription PCR.
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(Biotinylated anti-rat antibody for Lcn-2 (R&D) and alkaline
phosphatase–conjugated antibody for ED1 (Abcam, Cambridge, UK)).
Samples were incubated with avidin–biotin horseradish peroxidase
complex and visualized by incubating the sections with diamino-
benzidine (Sigma) and hydrogen peroxides. For ED1 detection,
slides were developed with 2-nitro-5-thiocyanobenzoic acid/5-bromo-
4-chloro-3-indolyl phosphate and counterstained with hematoxylin.
Protein concentration
Protein concentration was determined using the Bradford assay
(Bio-Rad, Hercules, CA).
ELISA
Supernatants were collected from cells and tissue was homogenized
and clarified. A volume of 100ml of each sample was applied to an
ELISA well plate previously covered with the anti-Lcn-2 (R&D) and
blocked for 1 h. After sample incubation, the detection anti-Lcn-2
antibody (R&D) was added. HRP-conjugated avidin (Invitrogen)
was incubated for 1 h, the color reagent (OPD tablets; Dako, Glostrup,
Denmark) was added, and color development was assessed.
Real-time reverse transcription PCR
Cellular RNA was isolated using the RNeasy mini kit (Qiagen,
Hilden, Germany), and kidney RNA was extracted with TRIzol
reagent (Invitrogen). Complementary DNA (cDNA) was synthesized
by using the iScript cDNA synthesis Kit (Bio-Rad), and quantitative
reverse transcription PCRs were performed using the SYBR Green
RT-PCR detection Kit (Bio-Rad). A measure of 1mg of cDNA was
used for the detection of PCNA, Ki-67, Lcn-2, IL-10, IL-1b, and
mannose receptor expression. Primers to detect Lcn-2-receptor and
megalin were purchased as validated primer sets from Qiagen. The
sequences, amplicon length, and annealing temperature for each
primer are given in Table 4. Results were normalized to glycer-
aldehyde 3-phosphate dehydrogenase as an internal control for stable
expression.
Statistical analysis
Data were analyzed using one-way analysis of variance, followed by
Newman–Keuls test analyses. Data are presented as the means
±s.e.m. with P values o0.05 considered significant.
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Figure S1. IL-10-transduced macrophages exhibit a predominant
anti-inflammatory phenotype.
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